Relationship with Excipient Providers Drawing Increasing Pharma Attention, BMS Exec Stresses; IPEC Urges Regulatory Pathway for New Excipients in GDUFA/PDUFA Comments

An important component in the ability of pharmaceutical innovators to bring their new products to market in the eclipsed timelines in which they need to function will be their relationship with excipient providers, a top manufacturing executive from Bristol-Myers Squibb (BMS) stressed to participants at the International Pharmaceutical Excipients Council of the Americas (IPEC-Americas)/ExcipientFest conference in San Juan, Puerto Rico in late April.

Providing the final keynote talk at the conference, BMS Pharmaceutical Operations Senior VP Ricardo Zayas made a compelling case for why this relationship has become increasingly important in pharmaceutical product development and to the financial viability of the companies involved. Zayas has responsibility for the strategic and operational leadership for BMS’ global supply chain.

Explaining that development to launch speed “is the single most important imperative right now” for an innovator company like BMS, Zayas stressed the need “now more than ever” to work with excipient suppliers “to reduce this.”

[CLICK HERE for the complete story. Nonsubscribers can get information on IPQ subscriptions/licensing and individual story purchasing by contacting Karen Bertani (Jonathan@ipq.org).]